China Resources Pharmaceutical Group Salute del bilancio
Salute finanziaria criteri di controllo 5/6
China Resources Pharmaceutical Group ha un patrimonio netto totale di CN¥97.1B e un debito totale di CN¥74.9B, che porta il suo rapporto debito/patrimonio netto a 77.1%. Le sue attività totali e le sue passività totali sono rispettivamente CN¥266.4B e CN¥169.2B. L'EBIT di China Resources Pharmaceutical Group è CN¥11.6B rendendo il suo rapporto di copertura degli interessi 8.3. Ha liquidità e investimenti a breve termine pari a CN¥33.1B.
Informazioni chiave
77.1%
Rapporto debito/patrimonio netto
CN¥74.87b
Debito
| Indice di copertura degli interessi | 8.3x |
| Contanti | CN¥33.08b |
| Patrimonio netto | CN¥97.12b |
| Totale passività | CN¥169.24b |
| Totale attività | CN¥266.36b |
Aggiornamenti recenti sulla salute finanziaria
Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Aug 30
We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Dec 06Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?
Sep 07These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
May 05Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?
Dec 15China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt
Aug 27Recent updates
China Resources Pharmaceutical Group Limited's (HKG:3320) Shares Climb 34% But Its Business Is Yet to Catch Up
Oct 07Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Aug 30China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Jun 01Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%
May 13China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697
Apr 28China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Apr 14China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697
Mar 28China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon
Jan 28We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Dec 06Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?
Sep 07Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?
Aug 02With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case
May 26These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
May 05China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 04Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?
Jan 24Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?
Dec 15China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price
Oct 18China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt
Aug 27China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15
May 29China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15
May 02China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's
Apr 07China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet
Mar 31Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?
Feb 21Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Dec 07China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate
Nov 10These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
Aug 29Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?
Aug 03Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?
May 03Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?
Apr 12Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Mar 17Analisi della posizione finanziaria
Passività a breve termine: Le attività a breve termine ( CN¥197.6B ) di 3320 superano le sue passività a breve termine ( CN¥144.0B ).
Passività a lungo termine: Le attività a breve termine di 3320 ( CN¥197.6B ) superano le sue passività a lungo termine ( CN¥25.2B ).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: Il rapporto debito netto/patrimonio netto ( 43% ) di 3320 è considerato alto.
Riduzione del debito: Il rapporto debito/patrimonio netto di 3320 si è ridotto da 91.5% a 77.1% negli ultimi 5 anni.
Copertura del debito: Il debito di 3320 è ben coperto dal flusso di cassa operativo ( 24.4% ).
Copertura degli interessi: I pagamenti degli interessi sul debito di 3320 sono ben coperti dall'EBIT ( 8.3 x copertura).